×
About 5,370 results

ALLMedicine™ Hypercalcemia Center

Research & Reviews  1,421 results

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04933539

Jan 14th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Cholangiocarcinoma
https://emedicine.medscape.com/article/277393-overview

Jan 12th, 2022 - Practice Essentials Cholangiocarcinomas (CCCs) are malignancies of the biliary duct system that may originate in the liver and extrahepatic bile ducts, which terminate at the ampulla of Vater. [1, 2, 3, 4, 5] CCCs are encountered in three anatomic...

99mTc-MDP Bone Scintigraphy and SPECT/CT of Extensive Subcutaneous Calcification in the...
https://doi.org/10.1097/RLU.0000000000003966
Clinical Nuclear Medicine; Viragh K, Khoshchehreh M et. al.

Jan 11th, 2022 - A 56-year-old woman with history of cosmetic buttock augmentation via mineral oil injection 20+ years ago presented with extensive abdominopelvic skin induration and hypercalcemia. The 99mTc-MDP bone scintigraphy performed for hypercalcemia reveal...

Early vs late initiation of sodium glycerophosphate: Impact on hypophosphatemia in pret...
https://doi.org/10.1016/j.clnu.2021.12.011
Clinical Nutrition (Edinburgh, Scotland); Ozer Bekmez B, Oguz SS

Jan 11th, 2022 - Early electrolyte and mineral imbalances have emerged as a conspicuous problem in very preterm babies since the revision of nutrition guidelines and the eventual implementation of early aggressive parenteral nutrition (PN). We opted to carry out a...

Hypercalcemia in IgG4-related disease: coincidental or associated? Case based review.
https://doi.org/10.1007/s00296-021-05076-y 10.1038/s41584-020-0500-7 10.1093/rheumatology/kez667 10.3906/sag-2006-375 10.1007/s12020-021-02714-0 10.1007/s13730-018-0358-6 10.1002/hed.26861 10.1111/j.1365-2559.1994.tb01356.x 10.1007/s12022-007-0001-0 10.1507/endocrj.EJ18-0428 10.1007/s00296-011-1999-3 10.1016/j.jecr.2021.100086 10.1056/NEJMoa040008
Rheumatology International; Üsküdar Cansu D, Cansu GB et. al.

Jan 8th, 2022 - Immunoglobulin (Ig) G4-related disease (IgG4RD) is a chronic autoimmune disorder characterized by dense lymphoplasmacytic infiltrations and fibrosis of storiform pattern. The most typical manifestations include major salivary or lacrimal gland inv...

see more →

Guidelines  3 results

Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494249
Journal of Clinical Oncology : Official Journal of the Am... Cook LB, Fuji S et. al.

Jan 19th, 2019 - Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical features and prognosis. ATL remains a challenging disease as a result of its diver...

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0023
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.

Feb 12th, 2017 - Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-r...

SEOM guidelines on hydroelectrolytic disorders.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239780
Clinical & Translational Oncology : Official Publication ... De las Peñas R, Escobar Y et. al.

Oct 12th, 2014 - Hydroelectrolytic disorders are one of the most common metabolic complications in cancer patients. Although often metabolic alterations affecting various ions are part of the manifestations of the oncological disease, even in the form of paraneopl...

see more →

Drugs  472 results see all →

Clinicaltrials.gov  52 results

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04933539

Jan 14th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT01572480

Dec 30th, 2021 - Background: SMM is a precursor condition to MM defined by the clinical parameters of M-protein >= 3.0 g/dL or bone marrow plasma cells >= 10% and absence of end organ disease. Risk of progression of high risk SMM at 5 years is 72-75% with median t...

Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial
https://clinicaltrials.gov/ct2/show/NCT03173976

Dec 6th, 2021 - This is a single arm open label phase 1b clinical trial assessing the safety and efficacy of neoadjuvant zoledronic acid in patients with resectable any grade chondrosarcoma as measured by pathological characteristics and recurrence free survival....

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04108195

Dec 3rd, 2021 - Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Overall rationale of study is that daratumumab in combination with talquetamab or t...

Circulating miRNA in Primary Hyperparathyroidism
https://clinicaltrials.gov/ct2/show/NCT03931109

Nov 16th, 2021 - Osteoporosis and osteopenia are chronic diseases disproportionately affecting the elderly. In the United States, the prevalence of osteoporosis is projected to increase from 10 million in 2005 to 14 million in 2025, due to population aging. Simila...

see more →

News  194 results

FDA Grants Fast Track Designation to Enobosarm for AR+/ER+ Metastatic Breast Cancer
https://www.onclive.com/view/fda-grants-fast-track-designation-to-enobosarm-for-ar-er-metastatic-breast-cancer

Jan 10th, 2022 - The FDA has granted a fast track designation to enobosarm as a potential therapeutic option for patients with androgen receptor (AR)–positive, estrogen receptor (ER)–positive, HER2-negative, metastatic breast cancer who progressed on a nonsteroida...

Novel Therapies Under Investigation for HR+ MBC
https://www.onclive.com/view/novel-therapies-under-investigation-for-hr-mbc

Nov 22nd, 2021 - Gabriel N. Hortobagyi, MD, FACP: In addition to the CDK [cyclin-dependent kinase]4/6 inhibitors, there is much interest in exploring and understanding mechanisms of resistance to these agents. There is a long list of proposed potential mechanisms ...

High real-world use of bone-modifying agents in mCSPC
https://www.mdedge.com/fedprac/article/247675/prostate-cancer/high-real-world-use-bone-modifying-agents-mcspc

Oct 20th, 2021 - Key clinical point: Bone-modifying agents (BMAs) are overused in the real world in patients with metastatic castration-sensitive prostate cancer (mCSPC). Major finding: Receipt of BMAs was reported in 23.

SIRT With Y90 Plus Chemotherapy Extends Survival for Intrahepatic Cholangiocarcinoma
https://www.onclive.com/view/sirt-with-y90-plus-chemotherapy-extends-survival-for-intrahepatic-cholangiocarcinoma

Sep 4th, 2021 - The addition of selective internal radiation therapy (SIRT) with Y90 resin microspheres to gemcitabine/cisplatin resulted in a median overall survival (OS) of 21.6 months (95% CI, 7.3-25.2) for patients with inoperable intrahepatic cholangiocarcin...

Talking Tumors: Filling Data Gaps in Multiple Myeloma
https://www.onclive.com/view/talking-tumors-filling-data-gaps-in-multiple-myeloma

Aug 17th, 2021 - We recently traveled to New York City, New York, for a State of the Science Summit™ on Multiple Myeloma. Although the treatment paradigm in multiple myeloma is guided by transplant eligibility, and grounded in the use of immunomodulatory drugs, pr...

see more →

Patient Education  6 results see all →